Faron Pharmaceuticals Oy
Records under this name other than the patents Faron Pharmaceuticals Oy holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 13 patents it holds.
Showing 1 to 4 of 4 · Back to Faron Pharmaceuticals Oy
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,534,423 | Method for inducing an elevated level of adenosine in an individual Term ended Term ended Nov 30, 2024 · From the USPTO record | Term ended | Term ended Nov 30, 2024 | From the USPTO record |
| US 7,910,097 | Common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1) and uses thereof Term ended Term ended Mar 25, 2023 · From the USPTO record | Term ended | Term ended Mar 25, 2023 | From the USPTO record |
| US 7,354,577 | Common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1) and uses thereof Term ended Term ended Mar 22, 2023 · From the USPTO record | Term ended | Term ended Mar 22, 2023 | From the USPTO record |
| US 8,119,651 | Compositions useful especially for treatment or prevention of metabolic syndrome Formerly held Lapsed on the fee record Ended Feb 21, 2016 · From the USPTO record | Lapsed on the fee record | Ended Feb 21, 2016 | From the USPTO record |